Immunic (NASDAQ:IMUX) Downgraded to Sell Rating by StockNews.com

StockNews.com cut shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a research note published on Saturday morning.

IMUX has been the subject of a number of other reports. D. Boral Capital reiterated a “buy” rating and set a $17.00 target price on shares of Immunic in a research report on Thursday. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Immunic in a research report on Friday. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $12.67.

Immunic Trading Up 6.6 %

Shares of Immunic stock opened at $1.26 on Friday. The firm has a market cap of $113.32 million, a PE ratio of -1.02 and a beta of 1.87. The stock has a 50 day moving average of $1.02 and a 200 day moving average of $1.26. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares during the last quarter. State Street Corp raised its position in Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares during the period. Jane Street Group LLC lifted its stake in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Immunic during the third quarter valued at approximately $50,000. Finally, HB Wealth Management LLC bought a new position in shares of Immunic during the fourth quarter valued at approximately $81,000. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.